Clinical trial · Interventional
Acupuncture for Chemotherapy-induced Peripheral Neuropathy
Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study
NCT01892852CI-TRIAL-00011387unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Peripheral Neuropathy | — | UNRESOLVED | — |
| Toxicity Due to Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acupuncture
- description
- Acupuncture treatment
- interventionNames
- Procedure: Acupuncture
- type
- NO_INTERVENTION
- label
- Control
- description
- No other active treatment or sham acupuncture for this symptoms
Primary outcomes (1)
- measure
- Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline
- timeFrame
- At baseline, 1, 2, 3, and 7 wks from baseline
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma. * Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta and/or Lyrica. Patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period. * Patients, or the legal guardians of patients, must have the ability to understand Korean, and be ble to provide informed consent. * ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2. * If the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception. Exclusion Criteria: * Other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and HIV. * Current active treatment for lymphoma or multiple myeloma * Ongoing local infection at or near the acupuncture point adopted in this trial. * Severe immunocompromised patients, leukopenia ( \< 4,000/㎣) or neutropenia ( \< 1,500/㎣) * Known coagulopathy, thrombocytopenia (\< 50,000/㎣), and taking heparin (including low molecular weight heparin) or Coumadin at any dose. * Serious emotional or mental problems that precludes study entry. * Mental and physical disability that precludes accurate acupuncture. * Serious systemic diseases such as active infection, severe heart disease, uncontrolled hypertension and diabetes mellitus. * Cardiac pacemaker. * Pregnant or breastfeeding * Acupuncture therapy within the previous 30 days * Concurrent other complementary and alternative therapy such as herbal agents, high dose vitamins, and etc.
References
Publications (0)
Data not yet available
No reference posted for this study.